Sernova Corp. (TSE:SVA - Get Free Report) reached a new 52-week low during trading on Monday . The stock traded as low as C$0.19 and last traded at C$0.19, with a volume of 36501 shares trading hands. The stock had previously closed at C$0.20.
Sernova Price Performance
The stock has a market cap of C$61.81 million, a P/E ratio of -1.46 and a beta of 1.35. The company has a 50 day simple moving average of C$0.23 and a 200 day simple moving average of C$0.25. The company has a current ratio of 0.32, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55.
Sernova Company Profile
(
Get Free Report)
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sernova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sernova wasn't on the list.
While Sernova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
